A Phase II Trial of Doxil, Carboplatin and Bevacizumab in Triple Negative Previously Untreated Metastatic Breast Cancer
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
The primary objective of this study is to determine the median progression free survival (PFS) and 1-year PFS after treatment with doxil, carboplatin and bevacizumab in patients with ER, PR, HER2neu negative metastatic breast cancer.
2 years
No
Deborah Toppmeyer, MD
Principal Investigator
UMDNJ/CINJ
United States: Institutional Review Board
040702
NCT00608972
January 2008
June 2014
Name | Location |
---|---|
Cooper Hospital/University Medical Center | Camden, New Jersey 08103 |
Saint Peter's University Hospital | New Brunswick, New Jersey 08901-1780 |
Cancer Institute of New Jersey (CINJ) | New Brunswick, New Jersey 08901 |
The Cancer Institute of New Jersey at Hamilton | Hamilton, New Jersey 08690 |